Table 2. Research data on endpoints reported in the clinical trials.
| Treatment mode | First author | ITT | Patients with resection | MPR rate | pCR rate | Incidence of TRAEs | Incidence of SAEs | Surgical delay rate | Conversion rate |
|---|---|---|---|---|---|---|---|---|---|
| ICI + chemo | Forde PM | 179 | 149 | 37% (66/179) | 24% (43/179) | 47% (82/176) | 19% (34/176) | 17% (31/179) | – |
| ICI + chemo | Zinner R | 13 | 13 | 85% (11/13) | 38% (5/13) | – | 15% (2/13) | – | – |
| ICI + chemo | Rothschild SI | 68 | 55 | 60% (33/55) | 15% (10/68) | – | – | – | – |
| ICI + chemo | Provencio M | 46 | 41 | 74% (34/46) | 57% (26/46) | 93% (43/46) | 30% (14/46) | 0 | – |
| ICI + chemo | Shu CA | 30 | 26 | 57% (17/30) | 33% (10/30) | – | 10% (3/30) | 0 | – |
| ICI + chemo | Tfayli A | 15 | 11 | 20% (3/15) | 7% (1/15) | – | 27% (4/15) | – | – |
| ICI + chemo | Yang CJ | 24 | 13 | – | 8% (2/24) | – | 25% (6/24) | 8% (2/24) | 13% (3/24) |
| ICI + chemo | Wang J | 72 | 72 | – | 29% (21/72) | – | 4% (3/72) | 0 | – |
| ICI + chemo | Shen D | 37 | 37 | 65% (24/37) | 46% (17/37) | 70% (26/37) | 11% (4/37) | 0 | – |
| ICI + chemo | Duan H | 23 | 20 | 43% (10/23) | 26% (6/23) | – | – | – | 9% (2/23) |
| Mono-ICI | Carbone D | 181 | 159 | 17% (30/181) | 6% (10/181) | 41% (75/181) | 9% (16/181) | – | – |
| Mono-ICI | Cascone T | 23 | 21 | 22% (5/23) | 9% (2/23) | – | 13% (3/23) | – | – |
| Mono-ICI | Eichhorn F | 15 | 15 | 27% (4/15) | 13% (2/15) | 53% (8/15) | 33% (5/15) | 7% (1/15) | – |
| Mono-ICI | Forde PM, Bott MJ | 22 | 20 | 41% (9/22) | 14% (3/22) | 23% (5/22) | 5% (1/22) | 0 | 32% (7/22) |
| Mono-ICI | Gao S | 40 | 37 | 38% (15/40) | 15% (6/40) | 53% (21/40) | 10% (4/40) | 5% (2/37) | – |
| Dual-ICIs | Cascone T | 21 | 16 | 38% (8/21) | 29% (6/21) | – | 10% (2/21) | – | – |
| Chemo | Forde PM | 179 | 135 | 9% (16/179) | 2% (4/179) | 51% (89/176) | 21% (37/176) | 13% (24/179) | – |
ICI, immune checkpoint inhibitor; chemo, chemotherapy; mono-ICI, single-agent immune checkpoint inhibitor; dual-ICIs, combination of two immune checkpoint inhibitors; ITT, intention-to-treat; MPR, major pathological response; pCR, complete pathological response; TRAE, treatment-related adverse event; SAE, severe adverse event.